Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO
Arie Belldegrun and David Chang are thinking big again, of course.
Today the pair running the biotech startup Allogene, a CAR-T company $ALLO looking to make history pioneering off-the-shelf cell therapeutics, outlined plans to sell 16 million shares in the company at $16 to $18 a share. That’s $288 million at the top of the range — though these 2 may not be satisfied with anything less than more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.